Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 11, Issue 7, Pages 541-559Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd3745
Keywords
-
Funding
- Chinese National 985 Project
- National Eye Institute
- US National Institutes of Health, VA Merit Award, Research to Prevent Blindness, King Abdulaziz City for Science and Technology (through the University of California San Diego Center of Excellence in Nanomedicine centre grant)
- BWF (Burroughs Wellcome Fund) Clinical Scientist Award in Translational Research
- National Science Foundation (NSF) [CMMI1031239, DMR1216461]
- US National Institutes of Health [EY019692]
- Research to Prevent Blindness, New York, USA
- Direct For Mathematical & Physical Scien
- Division Of Materials Research [1216461] Funding Source: National Science Foundation
Ask authors/readers for more resources
Blindness affects 60 million people worldwide. The leading causes of irreversible blindness include age-related macular degeneration, retinal vascular diseases and glaucoma. The unique features of the eye provide both benefits and challenges for drug discovery and delivery. During the past decade, the landscape for ocular drug therapy has substantially changed and our knowledge of the pathogenesis of ophthalmic diseases has grown considerably. Anti-angiogenic drugs have emerged as the most effective form of therapy for age-related macular degeneration and retinal vascular diseases. Lowering intraocular pressure is still the mainstay for glaucoma treatment but neuroprotective drugs represent a promising next-generation therapy. This Review discusses the current state of ocular drug therapy and highlights future therapeutic opportunities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
